ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Abou-Alfa on LY2157299 in HCC

Ghassan K. Abou-Alfa, MD
Published: Tuesday, Jan 28, 2014

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the phase II study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium.

Abou-Alfa says this is an interesting study because TGF-β1 is an important target in HCC. The study evaluated outcomes based on drops in alpha-fetoprotein (AFP), an associated marker with HCC. However, Abou-Alfa says AFP is not a prognostic or predictive marker.

The median survival was just shy of 6 months for the whole population, but the data for the patients who showed the biggest drop in AFP showed an overall survival of nearly 2 years.

Abou-Alfa says TGF-β1 needs to be studied further and evaluated from this perspective.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the phase II study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium.

Abou-Alfa says this is an interesting study because TGF-β1 is an important target in HCC. The study evaluated outcomes based on drops in alpha-fetoprotein (AFP), an associated marker with HCC. However, Abou-Alfa says AFP is not a prognostic or predictive marker.

The median survival was just shy of 6 months for the whole population, but the data for the patients who showed the biggest drop in AFP showed an overall survival of nearly 2 years.

Abou-Alfa says TGF-β1 needs to be studied further and evaluated from this perspective.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x